Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study

<div>Overall survival from time of discontinuation of the cBTKi (<i>n</i> = 739). Abbreviations: cBTKi = covalent bruton tyrosine kinase inhibitor; CI = confidence interval.</div>

Advances in Hematology

fig5

Figure 5

Figure 5: Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study 

Figure 5 | Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study 